SWOG clinical trial number
SWOG-9028

A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma Comparison of (1) VAD to VAD/ Quinine for Induction with Crossover to VAD/ Quinine for VAD Induction Failures; (2) Alpha-2b Interferon or Alpha-2b Interferon plus Prednisone for Remission Maintenance

Closed
Phase
Accrual
39%
Published
Abbreviated Title
A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma Comparison of (1) VAD to VAD/ Quinine for Induction with Crossover to VAD/ Quinine for VAD Induction Failures; (2) Alpha-2b…
Activated
10/01/1990
Closed
05/15/1994

Research committees

Myeloma

Publication Information Expand/Collapse

2018

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

2004

Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials

BGM Durie;J Jacobson;B Barlogie;J Crowley Journal of Clinical Oncology 22(10):1857-1863

2003

A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience

JL Jacobson;MA Hussein;B Barlogie;BGM Durie;JJ Crowley British Journal of Haematology 122:441-450

2001

Standard-dose therapy for multiple myeloma: the Southwest Oncology Group experience

J Crowley;J Jacobson;R Alexanian Seminars in Hematology 38(3):203-208

1998

Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group study.

SE Salmon;JJ Crowley;SP Balcerzak;RW Roach;SA Taylor;SE Rivkin;W Samlowski Journal of Clinical Oncology 16(3):890-896

1997

Alpha interferon plus alternate day prednisone (IFN/P) improves remission maintenance duration in multiple myeloma (MM) compared to IFN alone.

SE Salmon;JJ Crowley Proc of the American Society of Clinical Oncology 16:13a(#46)

Other Clinical Trials

SWOG Clinical Trial Number
S2213

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Research Committee(s)
Myeloma
Activated
12/01/2023
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2209

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
Research Committee(s)
Myeloma
Activated
05/30/2023
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
S2005

A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Research Committee(s)
Myeloma
Activated
06/24/2021
Accrual
10%
Open
Phase